Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Assets (2020 - 2025)

Pulse Biosciences has reported Assets over the past 6 years, most recently at $108.8 million for Q3 2025.

  • Quarterly results put Assets at $108.8 million for Q3 2025, up 16.89% from a year ago — trailing twelve months through Sep 2025 was $108.8 million (up 16.89% YoY), and the annual figure for FY2024 was $132.5 million, up 123.92%.
  • Assets for Q3 2025 was $108.8 million at Pulse Biosciences, down from $120.3 million in the prior quarter.
  • Over the last five years, Assets for PLSE hit a ceiling of $133.4 million in Q1 2025 and a floor of $39.5 million in Q1 2022.
  • Median Assets over the past 5 years was $74.8 million (2023), compared with a mean of $77.9 million.
  • Biggest five-year swings in Assets: tumbled 50.92% in 2022 and later surged 197.44% in 2025.
  • Pulse Biosciences' Assets stood at $59.2 million in 2021, then soared by 31.65% to $77.9 million in 2022, then decreased by 24.04% to $59.2 million in 2023, then skyrocketed by 123.92% to $132.5 million in 2024, then dropped by 17.89% to $108.8 million in 2025.
  • The last three reported values for Assets were $108.8 million (Q3 2025), $120.3 million (Q2 2025), and $133.4 million (Q1 2025) per Business Quant data.